tiprankstipranks
Trending News
More News >

Essa Pharma downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Joseph Catanzaro downgraded Essa Pharma (EPIX) to Neutral from Overweight with a price target of $2, down from $15. The company announced the discontinuation of masofaniten’s randomized Phase II trial in combination with enzalutamide in anti-androgen naive metastatic castration-resistant prostate cancer following an interim analysis that suggested the trial was unlikely to meet the primary endpoint, the analyst tells investors in a research note. With all other masofaniten studies are also being discontinued with the company evaluating all potential strategic options, Piper removed all value for masofaniten and downgraded the shares.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue